Sanofi forecasts slower profit growth amid generic competition
Sanofi forecast a slowdown in profit growth this year as generic competition ratchets up for multiple sclerosis drug Aubagio.
Earnings per share, excluding some items, are likely to grow at a low single-digit percentage at constant currencies, the Paris-based company said on Friday (Feb 3). The increase was 26 per cent last year.
Sanofi is facing challenges to its growth as its ageing medicine Aubagio will face cheaper competition in the US this spring. While Dupixent, a treatment for asthma and skin ailments, continues to drive Sanofi’s growth, the French drugmaker will need to increase spending on marketing this year as it launches new products including Beyfortus for preventing respiratory syncytial virus in kids and Altuviiio for hemophilia.
The drugmaker forecast that Dupixent sales could top 10 billion euros (S$14.3 billion) this year after its revenue soared 44 per cent in 2022.
Investors are also looking for signs that Sanofi is ready to engage in large acquisitions following its unsuccessful approach last year for Horizon Therapeutics, which was later bought by Amgen.
Adjusted earnings were 1.71 euros per share in the fourth quarter. Analysts expected 1.72 euros. BLOOMBERG
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
OUE wins tender to lease, develop new ‘zero-energy’ hotel at Changi Airport’s T2
Roku’s warning on ad-supported streaming competition clouds upbeat earnings
Stocks to watch: CLI, Great Eastern, MIT, Sheng Siong, iFast, OUE, Far East Orchard
ByteDance prefers TikTok shutdown in US if legal options fail: sources
CapitaLand Investment posts total revenue of S$650 million for Q1
Pricey coffee is here to stay as hoarding, heat hit Vietnam supply